Showing results (2251-2260 of 6,777) with videos related to
Sort By:
Pageof 678
Clinical Therapeutics|October 9, 2001
Factors associated with clinical assessment of overactive bladder and selection of treatmentA Diokno, P Lee, B H Zorn, et al.Clinical Therapeutics|October 9, 2001
Effect of raloxifene on serum triglycerides in postmenopausal women: influence of predisposing factors for hypertriglyceridemiaL Mosca, K Harper, S Sarkar, et al.Clinical Therapeutics|October 9, 2001
Methodology for identifying patients at high risk for osteoporotic fractureG Westfall, R Littlefield, A Heaton, et al.Clinical Therapeutics|July 7, 2001
Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's diseaseJ NajibClinical Therapeutics|July 7, 2001
A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibeF Ezzet, G Krishna, D B Wexler, et al.Clinical Therapeutics|July 7, 2001
A comparison of the skin permeation of three topical 0.5% fluorouracil formulations with that of a 5% formulationS Levy, K Furst, W ChernClinical Therapeutics|July 7, 2001
Efficacy of single-dose intravenous dolasetron versus ondansetron in the prevention of postoperative nausea and vomitingJ B WalkerClinical Therapeutics|July 7, 2001
Responsiveness of the Smoking Cessation Quality of Life (SCQoL) questionnaireJ W Shaw, S J Coons, S A Foster, et al.Clinical Therapeutics|September 18, 2001
Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trialW J Elliott, D A Calhoun, P T DeLucca, et al.Clinical Therapeutics|September 18, 2001
Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studiesH E Bays, P B Moore, M A Drehobl, et al.Pageof 678